Announced Fri, 8 May · 18:38 IST
Alkem Laboratories Limited has informed the Exchange regarding a press release dated May 08, 2026, titled "This is to Inform you regarding US FDA inspection conducted today at the Company'' s CRO facility located at Taloja.".
Business Updates View source PDF
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹5560.00
prior close
₹5585.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.3-0.8-1.0-1.2-1.1-2.0+0.1-1.3-1.6-2.2-5.8-4.6-0.1—
Up moveDown movePending
AI summary
US FDA conducted an unannounced inspection on May 8, 2026 at Alkem Laboratories' CRO facility in Taloja, Maharashtra. The inspection concluded with no Form 483 issued, which is a favorable outcome indicating no significant compliance observations were found during the audit. This appears to be a routine regulatory inspection rather than a targeted investigation based on prior concerns.
Likely market impact
No Form 483 issuance is positive for the company as it suggests the facility met regulatory standards during the inspection. No immediate shareholder action required.